Colorectal Cancer : Bulletin #3
This edition presents key opinion leader (KOL) views on recent developments in the Colorectal Cancer (CRC) market. Topics covered include: Bristol-Myers Squibb (BMS) announcing interim data from the Phase II, CheckMate-142 trial evaluating Opdivo (nivolumab), alone and in combination with Yervoy (ipilimumab), for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); Roche announcing data from two Phase I studies evaluating CEA-TCB (RG7802), alone and in combination with Tecentriq (atezolizumab), in patients with mCRC who have CEA-positive solid tumours; Incyte announcing the publication of Phase I/II data from the ongoing ECHO-204 trial evaluating the safety and efficacy of epacadostat (INCB024360) in combination with nivolumab for the treatment of CRC.
Reasons to Purchase
How do KOLs view interim data from the CheckMate-142 trial and do they think they will be adequate for Opdivo and Opdivo/Yervoy to gain regulatory approval as a dMMR- or MSI-H-mCRC therapy?
Given that only 5 percent of mCRC patients have dMMR or MSI-H biomarkers, is patient selection for Opdivo and Opdivo/Yervoy therapy likely to prove challenging?
Where will Opdivo, with or without Yervoy, be positioned within the dMMR- or MSI-H-mCRC treatment paradigm and is it likely to encounter competition from similarly-indicated therapies?
What do KOLs think of CEA-TCB’s mechanism of action and potential efficacy as a treatment for CEA-positive solid tumours in patients with mCRC?
Do KOLs think the combination of CEA-TCB with atezolizumab will demonstrate superior efficacy over single-agent immunotherapy?
If CEA-TCB/atezolizumab gains regulatory approval on the basis of later-stage data, what sort of indication do KOLs think the combination is likely to receive?
How do KOLs view epacadostat as a potential treatment for CRC and are they concerned by the lack of activity that it shows in combination with nivolumab?
Do KOLs think that the current Phase I data support the continued development of epacadostat/nivolumab as a therapy for mCRC and, if yes, where is the combination most likely to be used within the treatment paradigm if approved?